A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome

Rationale: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca2+/calmodulin (CaM)-dependent inactivation of L-type Ca2+ channels. Objective: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. Methods and Results: We generated and characterized the functional properties of induced pluripotent stem cell–derived cardiomyocytes from a patient with D130G-CALM2–mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell–derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca2+ cycling properties, and (3) diminished Ca2+/CaM-dependent inactivation of L-type Ca2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell–derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca2+/CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. Conclusions: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.

[1]  Bogdan Amuzescu,et al.  Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. , 2014, Assay and drug development technologies.

[2]  Nevan J Krogan,et al.  CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. , 2016, Cell stem cell.

[3]  Michael J. Ackerman,et al.  Identification and Functional Characterization of a Novel CACNA1C-Mediated Cardiac Disorder Characterized by Prolonged QT Intervals With Hypertrophic Cardiomyopathy, Congenital Heart Defects, and Sudden Cardiac Death , 2015, Circulation. Arrhythmia and electrophysiology.

[4]  E. Marbán.  Cardiac channelopathies , 2020, Nature.

[5]  Nuno A. Fonseca,et al.  Expression Atlas update—a database of gene and transcript expression from microarray- and sequencing-based functional genomics experiments , 2013, Nucleic Acids Res..

[6]  H. Nakahama,et al.  Generation of Cardiomyocytes from Pluripotent Stem Cells. , 2016, Methods in molecular biology.

[7]  A. Hodgkin,et al.  A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.

[8]  D. Sinnecker,et al.  Modeling Long-QT Syndromes with iPS Cells , 2013, Journal of Cardiovascular Translational Research.

[9]  Christopher N. Johnson,et al.  Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome–Associated Calmodulin Missense Variant, E141G , 2016, Circulation. Cardiovascular genetics.

[10]  Takeshi Tsuchiya,et al.  Novel Calmodulin Mutations Associated With Congenital Arrhythmia Susceptibility , 2014, Circulation. Cardiovascular genetics.

[11]  James A Thomson,et al.  High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.

[12]  Yoram Rudy,et al.  Regulation of Ca2+ and electrical alternans in cardiac myocytes: role of CAMKII and repolarizing currents. , 2007, American journal of physiology. Heart and circulatory physiology.

[13]  M. Horie,et al.  Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation and variant phenotypes. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  Charles C Hong,et al.  Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. , 2015, Journal of molecular and cellular cardiology.

[15]  N. Hellen,et al.  Action potential morphology of human induced pluripotent stem cell-derived cardiomyocytes does not predict cardiac chamber specificity and is dependent on cell density. , 2015, Biophysical journal.

[16]  Stefan R. Pulver,et al.  Ultra-sensitive fluorescent proteins for imaging neuronal activity , 2013, Nature.

[17]  D. T. Yue,et al.  Arrhythmogenesis in Timothy Syndrome is associated with defects in Ca2+-dependent inactivation , 2016, Nature Communications.

[18]  Peter Kohl,et al.  Simultaneous Voltage and Calcium Mapping of Genetically Purified Human Induced Pluripotent Stem Cell–Derived Cardiac Myocyte Monolayers , 2012, Circulation research.

[19]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[20]  Frank B Sachse,et al.  Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[22]  Nancy F. Hansen,et al.  An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval. , 2014, American journal of human genetics.

[23]  Thomas Meitinger,et al.  Calmodulin Mutations Associated With Recurrent Cardiac Arrest in Infants , 2013, Circulation.

[24]  Rosy Joshi-Mukherjee,et al.  Calmodulin mutations associated with long QT syndrome prevent inactivation of cardiac L-type Ca(2+) currents and promote proarrhythmic behavior in ventricular myocytes. , 2014, Journal of molecular and cellular cardiology.

[25]  Marielle Alders,et al.  A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence. , 2014, Journal of the American College of Cardiology.

[26]  Michael Christiansen,et al.  Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. , 2012, American journal of human genetics.

[27]  D. T. Yue,et al.  Preassociation of Calmodulin with Voltage-Gated Ca2+ Channels Revealed by FRET in Single Living Cells , 2001, Neuron.

[28]  Michael Z. Lin,et al.  High-fidelity optical reporting of neuronal electrical activity with an ultrafast fluorescent voltage sensor , 2014, Nature Neuroscience.

[29]  C. Luo,et al.  A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. , 1994, Circulation research.

[30]  J. Barc,et al.  A Mutation in CALM 1 Encoding Calmodulin in Familial Idiopathic Ventricular Fibrillation in Childhood and Adolescence , 2022 .

[31]  J. Prchal,et al.  Differential Sensitivity to JAK Inhibitory Drugs by Isogenic Human Erythroblasts and Hematopoietic Progenitors Generated from Patient‐Specific Induced Pluripotent Stem Cells , 2014, Stem cells.

[32]  S. Priori,et al.  CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism , 2004, Cell.

[33]  C. Luo,et al.  A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. , 1994, Circulation research.

[34]  S. Chow,et al.  Sample Size , 2019, Encyclopedic Dictionary of Archaeology.

[35]  D. Srivastava,et al.  Modeling Human Protein Aggregation Cardiomyopathy Using Murine Induced Pluripotent Stem Cells , 2013, Stem cells translational medicine.

[36]  Sean M. Wu,et al.  Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening , 2013, Stem Cell Research & Therapy.

[37]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[38]  M. Ackerman,et al.  CALM3 mutation associated with long QT syndrome. , 2015, Heart rhythm.

[39]  Kevin E. Healy,et al.  Calcium Transients Closely Reflect Prolonged Action Potentials in iPSC Models of Inherited Cardiac Arrhythmia , 2014, Stem cell reports.

[40]  M. Boutros,et al.  E-CRISP: fast CRISPR target site identification , 2014, Nature Methods.

[41]  C. Kane,et al.  Excitation–contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes , 2015, Front. Cell Dev. Biol..

[42]  Peter J. Schwartz,et al.  Arrhythmogenic Calmodulin Mutations Disrupt Intracellular Cardiomyocyte Ca2+ Regulation by Distinct Mechanisms , 2014, Journal of the American Heart Association.

[43]  Lai-Hua Xie,et al.  Arrhythmogenic consequences of intracellular calcium waves. , 2009, American journal of physiology. Heart and circulatory physiology.

[44]  D. Kass,et al.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. , 1999, Circulation research.

[45]  R. Parker,et al.  Sample Size , 2003 .